ATHN-3 Radiosynovectomy Study
ATHNdataset Used to Identify Outcomes and Malignancy Risk with Radiosynovectomy
THSNA 2016 (Chicago, April 14-16): One way of treating overgrowth of the synovial lining of joints in patients with hemophilia due to joint bleeding is by injecting a radioisotope into the joint space, called radiosynovectomy. Researchers affiliated with the American Thrombosis and Hemostasis Network (ATHN) reported on a retrospective look at any of these procedures at the Thrombosis and Hemostasis Summit of North America (THSNA) in a series of 3 posters. There were at least 196 procedures identified in 24,482 patients, although this may underestimate the number of such procedures as not all ATHN affiliates were reporting this data and the capture period varied by HTC. Adults with severe hemophilia or inhibitors were more likely to have the procedure. Interestingly, right sided injections were more common than left, and 16% of cases required additional joint surgeries/procedures. Additionally although radiosynovectomy has been used for years (more commonly outside the US), safety concerns have been raised due to exposure to P32 injections (the most common injection in the US) and a few cases of cancers involving the blood cells had been published years ago. In the data captured in ATHN, only 1 (0.5%) had colon cancer, and there were no cases of blood cell related cancers. There was no association found between having this procedure and cancer.